Business Description
Apellis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03753U1060
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.17 | |||||
Equity-to-Asset | 0.25 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | -0.22 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.26 | |||||
Beneish M-Score | 1.51 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.1 | |||||
3-Year EBITDA Growth Rate | -0.2 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | -31.5 | |||||
3-Year Book Growth Rate | -15.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.94 | |||||
9-Day RSI | 40.03 | |||||
14-Day RSI | 38.32 | |||||
6-1 Month Momentum % | 13.13 | |||||
12-1 Month Momentum % | -37.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.1 | |||||
Quick Ratio | 2.5 | |||||
Cash Ratio | 1.42 | |||||
Days Inventory | 647.93 | |||||
Days Sales Outstanding | 96.79 | |||||
Days Payable | 189.7 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.2 | |||||
Shareholder Yield % | -5.53 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 85.25 | |||||
Operating Margin % | -130.39 | |||||
Net Margin % | -133.29 | |||||
FCF Margin % | -150.16 | |||||
ROE % | -195.18 | |||||
ROA % | -62.02 | |||||
ROIC % | -300.53 | |||||
ROC (Joel Greenblatt) % | -442.7 | |||||
ROCE % | -74.23 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.36 | |||||
PB Ratio | 29.4 | |||||
Price-to-Tangible-Book | 29.4 | |||||
EV-to-EBIT | -11.63 | |||||
EV-to-Forward-EBIT | -48.41 | |||||
EV-to-EBITDA | -11.67 | |||||
EV-to-Forward-EBITDA | -118.59 | |||||
EV-to-Revenue | 14.58 | |||||
EV-to-Forward-Revenue | 7.44 | |||||
EV-to-FCF | -9.71 | |||||
Price-to-Net-Current-Asset-Value | 33.28 | |||||
Earnings Yield (Greenblatt) % | -8.6 | |||||
FCF Yield % | -10.3 |